Other substances

VS10

A protease inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

VS10 is an experimental SARS-CoV-2 3C-like protease inhibitor (Guo et al., 2021).

VS10 on PubChem

Synonyms

1,2-Benzisothiazol-3(2H)-one, 2-phenyl-

 

Structure image - VS10

C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3S2

Supporting references

Link Tested on Impact factor Notes Publication date
Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation
3CLpro Small molecule Enzyme assay In vitro In silico 		in silico; in vitro enzyme assay 4.83

The compound inhibited SARS-CoV-2 3C-like protease in vitro in a dose dependent manner with an IC50 of 0.2 μM.

 Feb/24/2021
Export (.csv)